Combined-modality strategy for gastrointestinal stromal tumors

Area of Science:

• Oncology
• Gastrointestinal Oncology
• Molecular Targeted Therapy

Background:

• Gastrointestinal stromal tumor (GIST) is the most common nonepithelial gastrointestinal malignancy.
• Most GISTs express the CD117 antigen, indicating KIT protein activation.
• Dysregulated KIT protein is a key oncogenic driver in GIST.

Purpose of the Study:

• To evaluate the efficacy of imatinib, a KIT-selective inhibitor, in managing GIST.
• To assess the potential benefits of neoadjuvant and adjuvant imatinib in combination with surgery.
• To explore imatinib's role in enhancing organ sparing and prolonging survival in high-risk GIST.

Main Methods:

• Review of clinical trials investigating imatinib for metastatic and primary GIST.
• Analysis of outcomes from trials assessing neoadjuvant imatinib for pharmacologic debulking.
• Evaluation of ongoing trials for adjuvant imatinib following surgical resection.

Main Results:

• Imatinib demonstrated partial response or stable disease in 82% of patients with metastatic GIST.
• Clinical trials are evaluating the efficacy of adjuvant and neoadjuvant imatinib.
• Combination therapy with surgery and imatinib is being studied for improved survival and reduced resistance.

Conclusions:

• Imatinib is a highly effective targeted therapy for GIST.
• Neoadjuvant and adjuvant imatinib, combined with surgery, hold promise for improving GIST treatment outcomes.
• This approach may serve as a model for targeted therapy combinations in other solid tumors.